Abstract
BackgroundDrug-eluting balloon (DEB) has become an alternative option to drug-eluting stent (DES) for the treatment of in-stent restenosis (ISR). However, the effect of drug-eluting balloon with regular bare-mental stent (BMS) in de novo coronary artery disease (CAD) is unclear. This meta-analysis aimed to evaluate the efficacy of DEB with regular BMS compared to BMS or DES in de novo CAD.MethodsRandomized controlled trials (RCTs) assessing the efficacy of DEB+BMS in comparison with BMS or DES were obtained by searching the PubMed, EMBASE, and Cochrane Library databases through January 2016. Primary endpoints were major adverse cardiac events (MACEs) and late lumen loss (LLL). Secondary endpoints included death, myocardial infarction (MI), target lesion revascularization (TLR), stent thrombosis (ST), binary restenosis, and minimum lumen diameter (MLD). Dichotomous and continuous data were presented as odds ratios (ORs) and mean differences (MDs) with 95% confidence intervals (CIs), respectively, and analyzed using a random-effects model.ResultsA total of 14 RCTs involving 2281 patients were included in this meta-analysis. DEB+BMS showed significantly less MACEs (OR: 0.67, 95%CI 0.45 to 0.99, P = 0.04) and reduced LLL (MD: -0.30 mm, 95%CI: -0.48 mm to -0.11 mm, P = 0.001) compared with BMS. Meanwhile, treatment with DEB+BMS had disadvantages over DES in terms of MACEs (OR: 1.94, 95%CI 1.24 to 3.05, P = 0.004), LLL (MD: 0.20 mm, 95%CI: 0.07 mm to 0.33 mm, P = 0.003), TLR (OR: 2.53, 95% CI 1.36 to 4.72, P = 0.003), and MLD (MD: -0.25 mm, 95%CI: -0.42 mm to -0.09 mm, P = 0.003).ConclusionsThis limited evidence demonstrated that treatment with DEB+BMS appears to be effective in de novo CAD. In addition, DEB+ BMS clearly showed superiority to BMS, but is inferior to DES in the treatment of patients with de novo CAD. Hence, DES (especially new generation DES) should be recommended for patients with de novo CAD.
Highlights
First-generation drug-eluting stents (DESs) reduce restenosis after percutaneous coronary intervention (PCI) by preventing vessel wall recoil and late negative remodeling, as well as restraining neointimal hyperplasia [1,2]
drug-eluting balloon (DEB)+bare-mental stent (BMS) showed significantly less major adverse cardiac events (MACEs) (OR: 0.67, 95%confidence intervals (CIs) 0.45 to 0.99, P = 0.04) and reduced late lumen loss (LLL) (MD: -0.30 mm, 95%CI: -0.48 mm to -0.11 mm, P = 0.001) compared with BMS
Treatment with DEB+BMS had disadvantages over DES in terms of MACEs (OR: 1.94, 95% CI 1.24 to 3.05, P = 0.004), LLL (MD: 0.20 mm, 95%CI: 0.07 mm to 0.33 mm, P = 0.003), target lesion revascularization (TLR) (OR: 2.53, 95% CI 1.36 to 4.72, P = 0.003), and minimum lumen diameter (MLD) (MD: -0.25 mm, 95%CI: -0.42 mm to -0.09 mm, P = 0.003)
Summary
First-generation drug-eluting stents (DESs) reduce restenosis after percutaneous coronary intervention (PCI) by preventing vessel wall recoil and late negative remodeling, as well as restraining neointimal hyperplasia [1,2] They are associated with many potential serious complications such as late stent thrombosis, non-homogenous drug delivery, and delayed vascularization, which makes bare-mental stent (BMS) preferred with shorter dual antiplatelet therapy in patients at high bleeding risk [3,4]. The effect of drug-eluting balloon with regular bare-mental stent (BMS) in de novo coronary artery disease (CAD) is unclear. This meta-analysis aimed to evaluate the efficacy of DEB with regular BMS compared to BMS or DES in de novo CAD.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.